Lung Cancer

Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.

Amivantamab-vmjw plus carboplatin and pemetrexed, administered with or without lazertinib, significantly improved progression-free survival vs chemotherapy alone in patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 19 deletions or L858R substitutions after progression on or after osimertinib.

Natalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.

Ravi Salgia, MD, PhD, discusses clinical gaps in the development of novel targets in lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as potential strategies or steps to address these gaps in clinical practice.

Millie Das, MD, highlights early efficacy signals with PARP inhibitors in patients with small cell lung cancer, how overall survival data from the phase 3 ADAURA trial confirm the efficacy of adjuvant osimertinib in patients with non–small cell lung cancer, and which patients may benefit most from immunotherapy as monotherapy or in combination with other agents.

Martin Wermke, MD, discusses why the novel agent may serve as a promising treatment option targeting DLL3.

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.

Combination treatment with atezolizumab, carboplatin, and pemetrexed showed activity in patients with advanced nonsquamous non–small cell lung cancer and untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment.

Angel Qin, MD, discusses several areas of active investigation in non–small cell lung cancer, and highlights questions necessitating future research in this disease space.

Adjuvant treatment with alectinib generated a statistically significant and clinically meaningful improvement in disease-free survival compared with platinum-based chemotherapy in patients with completely resected stage IB to IIIA, ALK-positive non–small cell lung cancer.

A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.

Moving on to discuss the treatment armamentarium in small cell lung cancer, expert oncologists consider current standards for frontline therapy.

Corey J. Langer, MD, outlines the prevalence of BRAF mutations in NSCLC and looked ahead to where the development pipeline of agents for the treatment of patients with BRAF-mutated NSCLC is headed.

Xiuning Le, MD, PhD, discusses ongoing and future investigations with osimertinib and chemotherapy in patients with metastatic lung cancer.

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Lyudmila A. Bazhenova, MD, discusses upcoming inhibitors of interest in the combination therapy space for patients with KRAS G12C–mutant NSCLC.

Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.

A supplemental biologics license application seeking the expanded approval of amivantamab-vmjw in combination with carboplatin plus pemetrexed for use in the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations has been submitted to the FDA.

Pasi A. Jänne, MD, PhD, discusses the advantages of bispecific ADCs that target both HER3 and EGFR; preliminary efficacy and safety data seen with BL-B01D1 in patients with non–small cell lung cancer; and the activity of this agent in patients with head and neck squamous cell carcinoma, small cell lung cancer, and nasopharynx cancer.

Gregory Peter Kalemkerian, MD, discusses the unmet needs associated with the investigation of combination chemoimmunotherapy in the frontline treatment of patients with extensive-stage small cell lung cancer.

The National Medical Products Administration of China has approved sunvozertinib for use in adult patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease has progressed on or following platinum-based chemotherapy.

Japan’s Ministry of Health, Labour, and Welfare has approved fam-trastuzumab deruxtecan-nxki for use in adult patients with unresectable advanced or recurrent, HER2-mutant non–small cell lung cancer that has progressed following chemotherapy.